Datasheet is currently unavailable. Try again or CONTACT US
WM46 Purified RNA
WM46-04-0500
10 µg
Liquid
Human
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
WM46 Purified RNA - WM46-04-0500
Melanoma, patient derived tumor, tumor models, skin cancer, xenograft
Human
Target Details
Total RNA was extracted and purified from cells using RNA isolation & purification kit according to manufacturers instructions. The RNA was diluted to 200 ng/µL in RNase free water. Concentration was determined at A260 using nanodrop ND-1000.
Application Details
Purified RNA is suitable for a number of molecular biology applications including but not limited to next generation sequencing and expression library construction, PCR, real-time PCR, microarray analysis, and transfection experiments.
Cell Line Data
Human Melanoma
RNA
V600E
R24C
WT
Hemizygous Deletion
Formulation
200 ng / µl by UV absorbance at 260 nm
RNase free water
None
None
Shipping & Handling
Dry Ice
Store vial at -20° C or COLDER. For extended storage, aliquot contents to minimize freeze/thaw cycles.
Expiration date is six (6) months from date of receipt.
Total RNA was prepared from cell line WM46. WM46 is a metastatic human melanoma cell line that displays a pigmented fibroblastic morphology. This cell line was established from left chest & abdomen in a 43-year-old female patient with level IV superficial spreading melanoma and a tumor thickness of 1.44. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses PTEN loss of function including hemizygous deletion, and R24C mutation at position 24 in the CDK4 gene. The R24C mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to cysteine (C). This mutation abolishes the ability of CDK4 to bind to p16(INK4a). WM46 cells produce xenograft tumors when injected into immunocompromised mice.
No test method can provide total assurance that the hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or any other infectious agents are absent. Thus, all blood products, including purified proteins derived from human blood sources, should be handled at Biosafety Level 2 as recommended by the CDC\NIH manual entitled Biosafety in Microbiological and Biomedical Laboratories for potentially infectious human serum, blood specimens or proteins derived from same. Source material for the human blood product supplied to your facility has been tested for the detection of HIV antibody, Hepatitis B surface antigen, antibody to Hepatitis C, HIV 1 antigen(s), antibody to HTLV - I/II, and syphilis by FDA guidelines. All units were found to be non-reactive/negative for these tests. All human blood source material is collected in FDA licensed centers and is tested with FDA approved test kits.; Cell Line Limited Use License Required. THIS PRODUCT IS SUBJECT TO AN END-USER LICENSE AGREEMENT (EULA). BY ACCEPTING THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF USE SET FORTH BELOW and SET FORTH IN THE EULA. THIS PRODUCT IS FOR IN VITRO RESEARCH USE ONLY. THERAPEUTIC, DIAGNOSTIC, OR VETERINARY USE IS PROHIBITED. This product may not be resold or transferred by the recipient and may be used only by the recipient, in the recipient’s facility and only for research use and other uses specifically permitted by the EULA. No other commercial use is allowed. “Commercial Use” means any and all uses of this product by recipient or others for monetary or other consideration, including providing services, supplying information or data to unaffiliated third parties, and resale or transfer of this product for any use. Recipient has no right to modify, derivatize, genetically engineer or otherwise create variations of this product or associated cells or cell lines. ROCKLAND AND WISTAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. The terms set forth herein and in the EULA shall be governed by the laws of the Commonwealth of Pennsylvania, USA. To obtain a COMMERCIAL USE license for this product, please contact Rockland Immunochemicals, Inc. Please contact a technical service representative for more information. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.